BioCentury | Apr 25, 2013
Distillery Therapeutics

Indication: Cancer

...treatment alone. Next steps could include further preclinical evaluation of EPHX2 inhibitors in cancer models. Arete Therapeutics Inc....
BioCentury | Nov 7, 2011
Company News

Galleon management update

...MacIntyre as SVP of drug discovery, formerly a SVP and head of drug discovery at Arete Therapeutics Inc....
BioCentury | Sep 24, 2009
Distillery Therapeutics

Indication

...cardiovascular disease. Next steps could include testing the inhibitor in animal models of cardiovascular disease. Arete Therapeutics Inc.'s...
BioCentury | Feb 23, 2009
Product Development

A more excellent choice

...turn inhibited by marketed drugs that include NSAIDs and leukotriene receptor antagonists, respectively. Sabry believes Arete...
...of causing vasodilation and reducing blood pressure while also exerting certain anti-inflammatory and analgesic effects. Arete...
...itself, as well as composition of matter and method of use for inhibitory analogs. Originally, Arete...
BioCentury | Feb 16, 2009
Clinical News

AR9281: Phase IIa started

...double-blind, placebo-controlled, U.S. Phase IIa trial to evaluate oral AR9281 in 150 treatment-naïve, pre-diabetic patients. Arete Therapeutics Inc....
BioCentury | Jan 15, 2009
Distillery Therapeutics

Indication: Cardiovascular disease

This week in therapeutics Indication Target/ marker/ pathway Summary Licensing status Publication and contact information Cardiovascular disease Cardiac hypertrophy Epoxide hydrolase (EPHX2); angiotensin II type 1 receptor (AGTR1) A study in rats suggests that inhibiting...
BioCentury | Jan 5, 2009
Clinical News

AR9281: Phase Ib data

...to 1,200 mg/day of oral AR9281 was well tolerated with no observed dose-related adverse events. Arete Therapeutics Inc....
BioCentury | Jul 14, 2008
Company News

Arete management update

Arete Therapeutics Inc. Hayward, Calif. Business: Cardiovascular, Inflammation Hired: James Sabry, chairman and former CEO of Cytokinetics Inc. , as president and CEO; he replaces Dinesh Patel WIR Staff Cardiovascular Inflammation...
BioCentury | Jul 9, 2008
Company News

Arete names Sabry CEO

...Cardiovascular, inflammation and metabolic company Arete (Hayward, Calif.) hired James Sabry as president and CEO. The...
...CEO. The chairman and former CEO of Cytokinetics (NASDAQ:CYTK) has been a strategic advisor to Arete...
BioCentury | Dec 10, 2007
Company News

Arete board of directors update

Arete Therapeutics Inc. , Hayward, Calif. Business: Cardiovascular, Inflammation Appointed: Donald Santel, formerly CEO of Actelion Ltd. 's CoTherix Inc. subsidiary WIR Staff Cardiovascular Inflammation...
Items per page:
1 - 10 of 17
BioCentury | Apr 25, 2013
Distillery Therapeutics

Indication: Cancer

...treatment alone. Next steps could include further preclinical evaluation of EPHX2 inhibitors in cancer models. Arete Therapeutics Inc....
BioCentury | Nov 7, 2011
Company News

Galleon management update

...MacIntyre as SVP of drug discovery, formerly a SVP and head of drug discovery at Arete Therapeutics Inc....
BioCentury | Sep 24, 2009
Distillery Therapeutics

Indication

...cardiovascular disease. Next steps could include testing the inhibitor in animal models of cardiovascular disease. Arete Therapeutics Inc.'s...
BioCentury | Feb 23, 2009
Product Development

A more excellent choice

...turn inhibited by marketed drugs that include NSAIDs and leukotriene receptor antagonists, respectively. Sabry believes Arete...
...of causing vasodilation and reducing blood pressure while also exerting certain anti-inflammatory and analgesic effects. Arete...
...itself, as well as composition of matter and method of use for inhibitory analogs. Originally, Arete...
BioCentury | Feb 16, 2009
Clinical News

AR9281: Phase IIa started

...double-blind, placebo-controlled, U.S. Phase IIa trial to evaluate oral AR9281 in 150 treatment-naïve, pre-diabetic patients. Arete Therapeutics Inc....
BioCentury | Jan 15, 2009
Distillery Therapeutics

Indication: Cardiovascular disease

This week in therapeutics Indication Target/ marker/ pathway Summary Licensing status Publication and contact information Cardiovascular disease Cardiac hypertrophy Epoxide hydrolase (EPHX2); angiotensin II type 1 receptor (AGTR1) A study in rats suggests that inhibiting...
BioCentury | Jan 5, 2009
Clinical News

AR9281: Phase Ib data

...to 1,200 mg/day of oral AR9281 was well tolerated with no observed dose-related adverse events. Arete Therapeutics Inc....
BioCentury | Jul 14, 2008
Company News

Arete management update

Arete Therapeutics Inc. Hayward, Calif. Business: Cardiovascular, Inflammation Hired: James Sabry, chairman and former CEO of Cytokinetics Inc. , as president and CEO; he replaces Dinesh Patel WIR Staff Cardiovascular Inflammation...
BioCentury | Jul 9, 2008
Company News

Arete names Sabry CEO

...Cardiovascular, inflammation and metabolic company Arete (Hayward, Calif.) hired James Sabry as president and CEO. The...
...CEO. The chairman and former CEO of Cytokinetics (NASDAQ:CYTK) has been a strategic advisor to Arete...
BioCentury | Dec 10, 2007
Company News

Arete board of directors update

Arete Therapeutics Inc. , Hayward, Calif. Business: Cardiovascular, Inflammation Appointed: Donald Santel, formerly CEO of Actelion Ltd. 's CoTherix Inc. subsidiary WIR Staff Cardiovascular Inflammation...
Items per page:
1 - 10 of 17